FDA Approves First Drug to Delay the Onset of Congestive Heart Failure in Dogs

US FDA approves first drug to delay heart failure in dogs

Jan 19 (Reuters) - Pharmaceutical company Boehringer Ingelheim said on Monday the U.S. Food and Drug Administration had approved ‍its chewable tablet, as the first drug to delay congestive heart failure in dogs with a type of early-stage heart disease....

FDA approves first drug to delay the onset of congestive heart failure in dogs

Heart disease affects approximately 10 percent of dogs in their lifetime1VETMEDIN® (pimobendan) from Boehringer Ingelheim is the only medication approved to treat preclinical mitral valve disease in dogsAn expansion of a conditional approval, the FDA authorization broadens the use of…

FDA Approves VETMEDIN, First Drug to Delay Onset of Congestive Heart Failure in Dogs

Boehringer Ingelheim, a global leader in animal health, recently announced that the U.S. Food and Drug Administration (FDA) has approved VETMEDIN (pimobendan) Chewable Tablets and VETMEDIN Solution (pimobendan oral solution), for the delay of onset of congestive heart failure (CHF) in dogs with Stage B2 preclinical myxomatous mitral valve disease (MMVD). VETMEDIN is the only medication approved to treat preclinical heart disease in dogs and exte…

US FDA approves first drug to delay heart failure in dogs - Regional Media News

Jan 19 (Reuters) - Pharmaceutical company Boehringer Ingelheim said on Monday the U.S. Food and Drug Administration had approved its chewable tablet, as the first drug to delay congestive heart failure in dogs with a type of early-stage heart disease. The approval covers dogs with a heart condition, known as myxomatous mitral valve disease, who show signs of heart enlargement but do not yet have symptoms. The FDA said Vetmedin can now be used to…